As of the latest Form 4 filed Jun 26, 2026.
What Definium Therapeutics, Inc. insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 24 most recent filings for DFTX.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-26 | 2026-06-25 | Sullivan Mark Chief Legal Officer | SSale | −13.0K | $45.03 | $586K | Yes (planned) | Form 4 ↗ |
| 2026-06-26 | 2026-06-25 | Karlin Daniel Chief Medical Officer | SSale | −10.0K | $45.03 | $452K | Yes (planned) | Form 4 ↗ |
| 2026-06-26 | 2026-06-25 | Roberts Brandi Chief Financial Officer | SSale | −3.01K | $45.03 | $136K | Yes (planned) | Form 4 ↗ |
| 2026-06-26 | 2026-06-25 | Barrow Robert Chief Executive Officer | SSale | −29.2K | $45.03 | $1.32M | Yes (planned) | Form 4 ↗ |
| 2026-06-26 | 2026-06-25 | Wiley Matthew T. Chief Commercial Officer | SSale | −2.87K | $45.03 | $129K | Yes (planned) | Form 4 ↗ |
| 2026-06-22 | 2026-06-22 | Barrow Robert Chief Executive Officer | AAward | +375K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-22 | 2026-06-22 | Wiley Matthew T. Chief Commercial Officer | AAward | +62.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-22 | 2026-06-22 | Roberts Brandi Chief Financial Officer | AAward | +62.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-22 | 2026-06-22 | Sullivan Mark Chief Legal Officer | AAward | +62.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-22 | 2026-06-22 | Karlin Daniel Chief Medical Officer | AAward | +100K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-15 | 2026-06-11 | CRYSTAL ROGER Director | AAward | +4.67K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-15 | 2026-06-11 | GRYSKA DAVID W Director | AAward | +4.67K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-15 | 2026-06-11 | Vallone Carol A Director | AAward | +4.67K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-15 | 2026-06-11 | Krebs Andreas Director | AAward | +4.67K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-15 | 2026-06-11 | Adsett Roger Director | AAward | +3.56K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-15 | 2026-06-11 | Bruhn Suzanne Louise Director | AAward | +4.67K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-26 | 2026-03-25 | Karlin Daniel Chief Medical Officer | SSale | −8.02K | $18.47 | $148K | Yes (planned) | Form 4 ↗ |
| 2026-03-26 | 2026-03-25 | Sullivan Mark Chief Legal Officer | SSale | −10.7K | $18.47 | $198K | Yes (planned) | Form 4 ↗ |
| 2026-03-26 | 2026-03-25 | Barrow Robert Chief Executive Officer | SSale | −24.4K | $18.47 | $451K | Yes (planned) | Form 4 ↗ |
| 2026-02-05 | 2026-02-03 | Wiley Matthew T. Chief Commercial Officer | AAward | +115K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-05 | 2026-02-03 | Roberts Brandi Chief Financial Officer | AAward | +150K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-05 | 2026-02-03 | Sullivan Mark Chief Legal Officer | AAward | +125K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-05 | 2026-02-03 | Karlin Daniel Chief Medical Officer | AAward | +150K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-05 | 2026-02-03 | Barrow Robert Chief Executive Officer | AAward | +320K | $0.00 | $0.00 | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also DFTX’s full analysis or the market-wide insider trading feed. The tabs above jump to DFTX’s other SEC data.
Source: SEC Form 4 filings for DFTX, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.